Helsinn, Specialised Therapeutics Australia deal

Helsinn granted Specialised exclusive rights to develop and commercialize anamorelin in Australia and New Zealand to treat cachexia/anorexia in patients with non-small cell lung cancer (NSCLC). Speci...